Expression and Clinical Relevance of p53 and BCL-2 in Bladder Cancer


Qadam I. K., Kaygın P., Dirican O., Bozkurt Ö. F., Güler Şimşek G., Husseını A. A., ...Daha Fazla

VOPROSY ONKOLOGII, cilt.72, sa.1, ss.1-8, 2026 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 72 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.37469/0507-3758-2026-72-1-of-2392
  • Dergi Adı: VOPROSY ONKOLOGII
  • Derginin Tarandığı İndeksler: Scopus, BIOSIS, EMBASE
  • Sayfa Sayıları: ss.1-8
  • İstanbul Gelişim Üniversitesi Adresli: Evet

Özet

Introduction. Bladder cancer is a prevalent malignancy with high recurrence and progression rates. Molecular markers like p53 and BCL-2 are implicated in tumor behavior — p53 in tumor suppression and BCL-2 in apoptosis inhibition — yet their clinical significance remains unclear. This study inves- tigates the expression of p53 and BCL-2 in bladder cancer tissues and their associations with key clinical and pathological features to inform more personalized patient management.

Materials and Methods. Immunohistochemical analysis was performed on bladder cancer tissue samples to assess p53 and BCL-2 expression levels. Correlations with tumor grade, invasiveness, gender, age, and smoking status were examined.

Results. p53 expression was significantly higher in can- cerous tissues than in normal tissues (p < 0.00001) and was associated with high-grade tumors (p = 0.03156). No signif- icant difference in BCL-2 expression was observed between cancerous and normal tissues (p = 0.19706). No significant correlations were found between p53 and BCL-2 expression or with the clinical factors.

Conclusion. The overexpression of p53 in high-grade blad- der cancer tissues highlights its potential role as a biomarker for tumor aggressiveness, whereas BCL-2 shows limited prog- nostic relevance.